Evidence map›Paper›PMID 30813596›Full record

ArticleInternational journal of molecular sciences2019

Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.

Meagan B Myers, Karen L McKim, Malathi Banda, Nysia I George, Barbara L Parsons

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meagan B MyersDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA. meagan.myers@fda.hhs.gov.
Karen L McKimDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA. karen.mckim@fda.hhs.gov.
Malathi BandaDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA. malathi.banda@covance.com.
Nysia I GeorgeDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA. nysiainet@gmail.com.
Barbara L ParsonsDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA. barbara.parsons@fda.hhs.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Information regarding the role of low-frequency hotspot cancer-driver mutations (CDMs) in breast carcinogenesis and therapeutic response is limited. Using the sensitive and quantitative Allele-specific Competitor Blocker PCR (ACB-PCR) approach, mutant fractions (MFs) of six CDMs (

Indexed as

Mutation RatePrecision MedicineAllelesBreast NeoplasmsCarcinoma, Ductal, BreastErb-b2 Receptor Tyrosine KinasesFemaleFluoresceinHumansMiddle AgedMutationNeoplasm InvasivenessPhosphatidylinositol 3-KinasesPolymerase Chain ReactionProto-Oncogene Proteins B-rafERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluoresceinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafbreast cancercancer-driverheterogeneityinvasive ductal carcinomamutationPIK3CAsubclonalTNBCtriple-negative breast cancer

Identifiers

PMID30813596
PMCPMC6429455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.